Default header image

Dr. Byram Bridle

Dr. Byram W. Bridle
PhD

Links out: University of Guelph Experts, Department of Pathobiology

Current Positions:

  • Associate Professor of Viral Immunology – Department of Pathobiology, University of Guelph, Ontario Veterinary College
  • Faculty Affiliate – One Health Institute, University of Guelph

Seeking Partnerships in the Areas of:

Biotherapies for cancer treatment, Cancer immunotherapy, Cancer treatment without toxicities, Minimizing therapy toxicity, Oncolytic virotherapy, Viruses that Replicate in and kill cancerous cells

Keywords: oncology, cancer therapeutics, immunotherapy, oncolytic virotherapy, translational oncology and clinical studies

Education and Employment Background:

  • BSc – Biomedical Science (University of Guelph, Guelph, ON) 
  • MSc – Immunology (University of Guelph, Guelph, ON) 
  • PhD – Immunology (University of Guelph, Guelph, ON) 
  • Postdoctoral fellowship – Oncolytic Immunotherapy (McMaster University, Hamilton, ON)

Research Themes & Interests

Research in the Bridle lab has two arms:
One is to develop novel, highly targeted biotherapies for the treatment of cancers. In an effort to kill malignant cells with minimal bystander damage to normal tissues, two approaches are combined:
1. cancer immunotherapy that directs the power of a patient’s immune system against their own tumour(s) and,
2. oncolytic virotherapy, which utilizes viruses that replicate in and kill only cancerous cells. The exquisite specificity, systemic targeting capability and short treatment windows of these therapies hold promise that cancer patients might be effectively treated with reduced side effects and at minimal cost. The goal is to translate the most promising iterations of these therapies into clinical trials in companion animals as a stepping stone towards testing in human patients.

A second emphasis of the lab is the study of host responses to viruses. Specifically, efforts are being invested into understanding the mechanisms underlying virus-induced cytokine storms. We have identified a critical role of signaling through the type I interferon receptor in the negative regulation of an extensive network of cytokines. Notably, we have also discovered that cytokine responses to viruses are often very different between females and males and are seeking to understand why.

Select publications:

Peer Reviewed Articles
  1. Rosales Gerpe MC, van Lieshout LP, Domm JM, van Vloten JP, Datu J, Ingrao JC, Yu DL, de Jong J, Moraes TJ, Krell PJ, Bridle BW, Wootton SK. Optimized pre-clinical grade production of two novel lentiviral vector pseudotypes for lung gene deliveryHuman Gene Therapy 2020 Apr;31(7-8):459-471.
  2. Pol JG, Bridle BW, Lichty BD. Detection of tumor antigen-specific T-cell responses after oncolytic vaccinationMethods in Molecular Biology 2020;2058:191-211.
  3. van Vloten JP, Klafuric EM, Karimi K, McFadden G, Petrik JJ, Wootton SK, Bridle BW. Quantifying antibody responses induced by antigen-agnostic immunotherapiesMolecular Therapy – Methods and Clinical Development  2019 Jul 12;14:189-196.
  4. Yu DL, Stegelmeier AA, Chow N, Rghei AD, Matuszewska K, Lawler J, Bridle BW*, Petrik JJ*, Wootton SK*. AAV-mediated expression of 3TSR inhibits tumor and metastatic lesion development and extends survival in a murine model of epithelial ovarian carcinomaCancer Gene Therapy  2020 May;27(5):356-367. *co-senior author
  5. Stegelmeier AA, van Vloten JP, Mould RC, Klafuric EM, Minott JA, Wootton SK, Bridle BW, Karimi K. Myeloid cells during viral infections and inflammationViruses  2019 Feb 19;11(2):168.
  6. van Vloten JP, Santry LA, McAusland TM, Karimi K, McFadden G, Petrik JJ, Wootton SK, Bridle BW. Quantifying antigen-specific T cell responses when using antigen-agnostic immunotherapiesMolecular Therapy – Methods and Clinical Development  2019 Jan 29;13:154-166.
  7. Pol JG, Atherton MJ, Bridle BW, Stephenson KB, Le Boeuf F, Hummel JL, Martin CG, Pomoransky J, Breitbach CJ, Diallo JS, Stojdl DF, Bell JC, Wan Y, Lichty BD. Development and applications of oncolytic Maraba virus vaccinesOncolytic Virotherapy  2018 Nov 26;7:117-128.
  8. Matuszewska K, Santry LA, van Vloten JP, AuYeung AWK, Major PP, Lawler J, Wootton SK, Bridle BW, Petrik J. Combining vascular normalization with an oncolytic virus enhances immunotherapy in a preclinical model of advanced-stage ovarian cancerClinical Cancer Research  2019 Mar 1;25(5):1624-1638.
  9. Rosales Gerpe MC, van Vloten JP, Santry LA, de Jong J, Mould RC, Pelin A, Bell JC, Bridle BW, Wootton SK. Use of precision-cut lung slices as an ex vivo tool for evaluating viruses and viral vectors for gene and oncolytic therapyMolecular Therapy – Methods and Clinical Development  2018 Aug 4;10:245-256.
  10. Santry LA, McAusland TM, Susta L, Wood GA, Major PP, Petrik JJ, Bridle BW, Wootton SK. Production and purification of high-titer Newcastle disease virus for use in preclinical mouse models of cancer. Molecular Therapy – Methods and Clinical Development  2017 Oct 16;9:181-191.
  11. van Vloten JP, Workenhe ST, Wootton SK, Mossman KL, Bridle BW.
  12. van Vloten JP, Workenhe ST, Wootton SK, Mossman KL, Bridle BW. Critical interactions between immunogenic cancer cell death, oncolytic viruses, and the immune system define the rational design of combination immunotherapies. Journal of Immunology  2018 Jan 15;200(2):450-458.
  13. Hummel J, Bienzle D, Morrison A, Cieplak M, Stephenson K, DeLay J, Woods JP, Lichty BD, Bridle BW. Maraba virus-vectored cancer vaccines represent a safe and novel therapeutic option for cats. Scientific Reports  2017 Nov 16;7(1):15738.
  14. Mould RC, van Vloten JP, AuYeung AWK, Karimi K, Bridle BW.  Immune response in the thyroid cancer microenvironment: making immunotherapy a possible mission.  Endocrine Related Cancer2017 Sep 14. pii: ERC-17-0316.
  15. Mould RC, AuYeung AWK, van Vloten JP, Susta L, Mutsaers AJ, Petrik JJ, Wood GA, Wootton SK, Karimi K, Bridle BW.  Enhancing Immune Responses to Cancer Vaccines Using Multi-Site Injections.Scientific Reports2017 Aug 16;7(1):8322. 
  16. Allison KE, Coomber BL, Bridle BW.  Metabolic reprogramming in the tumour microenvironment: a hallmark shared by cancer cells and T lymphocytes.Immunology2017 Oct;152(2):175-184. 
  17. Kozak RA, Hattin L, Biondi MJ, Corredor JC, Walsh S, Xue-Zhong M, Manuel J, McGilvray ID, Morgenstern J, Lusty E, Cherepanov V, McBey BA, Leishman D, Feld JJ, Bridle B, Nagy É.  Replication and oncolytic activity of an avian orthoreovirus in human hepatocellular carcinoma cells.Viruses2017 Apr 24;9(4). pii: E90. 
  18. Bridle BW, Nguyen A, Salem O, Zhang L, Koshy S, Clouthier D, Chen L, Pol J, Swift SL, Bowdish DM, Lichty BD, Bramson JL, Wan Y.  Privileged antigen presentation in splenic B cell follicles maximizes T cell responses in prime-boost vaccination.Journal of Immunology2016 Jun 1;196(11):4587-95. 
  19. Bridle BW, Clouthier D, Zhang L, Pol J, Chen L, Lichty BD, Bramson JL, Wan Y.  Oncolytic vesicular stomatitis virus quantitatively and qualitatively improves primary CD8+ T-cell responses to anticancer vaccines.  Oncoimmunology2013 Aug 1;2(8):e26013.
  20. Bridle BW, Chen L, Lemay CG, Diallo JS, Pol J, Nguyen A, Capretta A, He R, Bramson JL, Bell JC, Lichty BD, Wan Y.  HDAC inhibition suppresses primary immune responses, enhances secondary immune responses, and abrogates autoimmunity during tumor immunotherapy.Molecular Therapy2013 Apr;21(4):887-94.  
  21. Bridle BW.  Neuroendocrine cancer vaccines in clinical trials.Expert Review of Vaccines2011 Jun;10(6):811-23. Review. 
  22. Bridle BW, Stephenson KB, Boudreau JE, Koshy S, Kazdhan N, Pullenayegum E, Brunellière J, Bramson JL, Lichty BD, Wan Y.  Potentiating cancer immunotherapy using an oncolytic virus.Molecular Therapy2010 Aug;18(8):1430-9. 
  23. Bridle BW, Li J, Jiang S, Chang R, Lichty BD, Bramson JL, Wan Y.  Immunotherapy can reject intracranial tumor cells without damaging the brain despite sharing the target antigen.Journal of Immunology2010 Apr 15;184(8):4269-75. 
  24. Bridle BW, Hanson S, Lichty BD. Combining oncolytic virotherapy and tumour vaccination.Cytokine and Growth Factor Reviews2010 Apr-Jun;21(2-3):143-8. Review. 
  25. Bridle BW, Boudreau JE, Lichty BD, Brunellière J, Stephenson K, Koshy S, Bramson JL, Wan Y.  Vesicular stomatitis virus as a novel cancer vaccine vector to prime antitumor immunity amenable to rapid boosting with adenovirus.Molecular Therapy2009 Oct;17(10):1814-21. 

PubMed Compilation for additional publications by Dr. Bridle: Link Out

Lay Scientific Articles

Highlights:

  • 2010: Featured in Ontario Institute for Cancer Research annual report as one of the “next generation of cancer researchers” and a “rising star” that should be retained in Ontario (pg. 20 of report).
  • 2014: Voted honourary class president by the Doctor of Veterinary Medicine (DVM) class of 2017 (University of Guelph); Monetary donation made in Dr. Bridle’s honour by the DVM class of 2017 to the Guelph Giants Special Hockey organization in recognition of teaching excellence.
  • 2015: Terry Fox Research Institute New Investigator Award; Voted by the DVM classes of 2015-17 to receive the Carl J. Norden Distinguished Teaching Award (“the highest teaching award given by each North American Veterinary College”).
  • 2019: Monetary donation made in Dr. Bridle’s honour by the DVM class of 2020-22 to the Down Syndrome Research Foundation in recognition of teaching excellence.
  • 2020: Voted honourary class president by the DVM class of 2023.
  • 2018-present: Member, CIHR Virology and Viral Pathogenesis grant review panel
  • Member, American Society of Gene & Cell Therapy

Coverage of the Bridle Lab in Media: 

The Bridle Lab is currently funded by:

  • The Natural Sciences and Engineering Research Council of Canada (NSERC)
  • Canadian Institutes of Health Research – Institute for Cancer Research
  • The Terry Fox Research Institute
  • National Centre of Excellence in Biotherapeutics for Cancer Treatment (BioCanRx)
  • Network of Centres of Excellence in Biotherapies for Cancer Treatment
  • The Pet Trust Foundation
  • The Smiling Blue Skies Cancer Fund
  • Canadian Foundation for Innovation – John R. Evans Leaders Fund
  • Ministry of Research and Innovation Ontario Research Fund – Research Infrastructure Program
  • Canadian Cancer Society Research Institute
  • Cancer Research Society

The Bridle Lab is part of the…

  • Canadian Oncolytic Virus Consortium
  • Network of Centres of Excellence in Biotherapies for Cancer Treatment (founding member)
  • Canadian Society of Immunology
  • Institute for Comparative Cancer Investigation
  • Dog Osteosarcoma Group: Biomarkers Of Neoplasia (DOG BONe)

Contact

Email:  bbridle@uoguelph.ca
Phone: 519-824-4120 x 54657
Office: PAHL 4834

Ontario Veterinary College
University of Guelph
50 Stone Road E.,
Guelph, ON, Canada, N1G 2W1